US20210128514A1 - Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker - Google Patents
Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker Download PDFInfo
- Publication number
- US20210128514A1 US20210128514A1 US17/146,010 US202117146010A US2021128514A1 US 20210128514 A1 US20210128514 A1 US 20210128514A1 US 202117146010 A US202117146010 A US 202117146010A US 2021128514 A1 US2021128514 A1 US 2021128514A1
- Authority
- US
- United States
- Prior art keywords
- blocker
- composition
- calcium channel
- metabolite
- calmodulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the invention relates to methods and compositions for the treatment and prevention of broad spectrum of viral ailments, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- compositions comprising a blocker selected from the group consisting of calcium channel blockers, metabolites thereof, calmodulin blockers and metabolites thereof that have been used to treat medical conditions unrelated to viral infections can effectively suppress intracellular replication of multiple viral species and prevent and treat diseases caused by a wide spectrum of acute or chronic viral infection.
- a blocker selected from the group consisting of calcium channel blockers, metabolites thereof, calmodulin blockers and metabolites thereof that have been used to treat medical conditions unrelated to viral infections
- these agents also have a beneficial inhibitory effect upon the host immune response to suppress the severity of the host's immune response to viral as well as other foreign antigens.
- compositions comprising a blocker selected from the group consisting of calcium channel blockers, metabolites thereof.
- calmodulin blockers and metabolites thereof also help protect the host from other exaggerated pathological conditions such as bacterial infections, bacterial exotoxins and endotoxins.
- these agents afford special protective benefits for isolated bacterial infections, mixed bacterial infections, isolated vital infections, mixed viral infections, mixed/combined/superimposed viral and bacterial infections.
- these agents can be beneficial for other non-infectious diseases or pathological states such as auto-immune processes psoriasis, autoimmune thryoiditis, autoimmune neuritis, autoimmune pericarditis, autoimmune pneumonitis, or any other type of autoimmune process.
- these agents can be beneficial for other non-infectious diseases or pathological states such as cell mediated allergic reactions to latex gloves, nickel or other metal allergies, or any other pathological immune response.
- the invention provides methods and compositions for the treatment and prevention of broad spectrum infectious, inflammatory and autoimmune ailments in human beings.
- the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a mammal for any viral disease that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the past ribosomal RNA to protein translation transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- the invention provides a pharmaceutical composition for the treatment and prevention of broad spectrum virus ailments, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions in animals and human beings, said composition comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- the calcium channel blocker is verapamil, diltiazem or felodipine; and the calmodulin blocker is trifluoperazine.
- the composition is in the form of a cream, spray, aerosol, powder, liquid for nebulization, gel, ointment or patch.
- the composition is in the form of a tablet, a sustained release formulation for systemic use.
- the composition is in the form of a sterile solution for parenteral injection.
- the invention provides a method of manufacturing a medicament intended for the prevention, and treatment of viral infections characterized in that the medicament is a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof; and admixed with a pharmaceutical acceptable diluent or carrier.
- the blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.
- Kits comprising pharmaceutical compositions of the invention formulated in sterile unit dosage forms suitable for administration to patients, includes instructions for use in written, oral, videotape, compact disc, other digital electronic form, or other recorded media, are contemplated.
- the invention provides a kit comprising the above-described compositions and an instruction for using the combination in treating, improving, curing or preventing viral infections.
- the appropriate dosage and frequency of treatment may vary depending on the specific symptoms and signs exhibited by the patient, or the clinical situation for prophylactic uses. Other health related factors should also be considered.
- the patient After a couple of hours the patient then continued to apply repeated small local applications of 0.1 ml intranasally and orally to throat twice more when the symptoms of nasal congestion started to recurred and again prior to going to sleep that night.
- Patient B with recurrent cold sores was given Verapamil 200 mg/ml and asked to apply at the first signs of a cold sore.
- HIV patient took Verapamil 240 mg (120 mg of verapamilSR) twice daily for 2 weeks before repeat blood work and showed significant rise in T4 helper counts.
Abstract
In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, of calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier, and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.
Description
- The invention relates to methods and compositions for the treatment and prevention of broad spectrum of viral ailments, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- A novel class of antiviral commands has now been discovered which has been found to exhibit a particularly favorable broad spectrum of antiviral properties through all classes of viruses. The inventor has discovered that pharmaceutical compositions comprising a blocker selected from the group consisting of calcium channel blockers, metabolites thereof, calmodulin blockers and metabolites thereof that have been used to treat medical conditions unrelated to viral infections can effectively suppress intracellular replication of multiple viral species and prevent and treat diseases caused by a wide spectrum of acute or chronic viral infection. In addition to direct antiviral effects due to the suppression of viral replication and suppression of viral release from infected host cells, the inventor has also observed that these agents also have a beneficial inhibitory effect upon the host immune response to suppress the severity of the host's immune response to viral as well as other foreign antigens.
- Since a significant portion of the pathologic damage done to the host during an infection or other types pathological diseases are a result damage to the host tissues from the immune systems indiscriminant damage to healthy and often uninfected host cells near or remote to the site of infection. These pharmaceutical compositions comprising a blocker selected from the group consisting of calcium channel blockers, metabolites thereof. calmodulin blockers and metabolites thereof also help protect the host from other exaggerated pathological conditions such as bacterial infections, bacterial exotoxins and endotoxins.
- As a result these agents afford special protective benefits for isolated bacterial infections, mixed bacterial infections, isolated vital infections, mixed viral infections, mixed/combined/superimposed viral and bacterial infections.
- As well these agents can be beneficial for other non-infectious diseases or pathological states such as auto-immune processes psoriasis, autoimmune thryoiditis, autoimmune neuritis, autoimmune pericarditis, autoimmune pneumonitis, or any other type of autoimmune process.
- As well these agents can be beneficial for other non-infectious diseases or pathological states such as cell mediated allergic reactions to latex gloves, nickel or other metal allergies, or any other pathological immune response.
- These are all examples of pathological conditions in animals of when the animals own immune response becomes excessive, and instead of protecting the animal, is actually damaging to the animal. This reduction in inflammation and damage to host is theorized by the inventor to be potentially an inhibitory effect of calcium channel blockers and calmodulin blockers on the movement and migration of inflammatory cells involved in the host response to these antigen into the sites of the pathologic or exaggerated immune response.
- Thus, the invention provides methods and compositions for the treatment and prevention of broad spectrum infectious, inflammatory and autoimmune ailments in human beings.
- In the broadest aspect the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a mammal for any viral disease that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the past ribosomal RNA to protein translation transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- Accordingly, in one aspect, the invention provides a pharmaceutical composition for the treatment and prevention of broad spectrum virus ailments, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions in animals and human beings, said composition comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
- Preferably, the calcium channel blocker is verapamil, diltiazem or felodipine; and the calmodulin blocker is trifluoperazine.
- Preferably, the composition is in the form of a cream, spray, aerosol, powder, liquid for nebulization, gel, ointment or patch.
- Preferably, the composition is in the form of a tablet, a sustained release formulation for systemic use.
- Preferably, the composition is in the form of a sterile solution for parenteral injection.
- In a still yet further aspect, the invention provides a method of manufacturing a medicament intended for the prevention, and treatment of viral infections characterized in that the medicament is a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof; and admixed with a pharmaceutical acceptable diluent or carrier.
- Preferably, the blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.
- Kits comprising pharmaceutical compositions of the invention formulated in sterile unit dosage forms suitable for administration to patients, includes instructions for use in written, oral, videotape, compact disc, other digital electronic form, or other recorded media, are contemplated.
- Thus, in a further aspect, the invention provides a kit comprising the above-described compositions and an instruction for using the combination in treating, improving, curing or preventing viral infections.
- The appropriate dosage and frequency of treatment may vary depending on the specific symptoms and signs exhibited by the patient, or the clinical situation for prophylactic uses. Other health related factors should also be considered.
- In order that the invention may be better understood, preferred embodiments will now be described by way of example only with reference to the following Examples.
- 53 year old male with symptoms of viral upper respiratory infection started experiencing nasal congestion and nasal discharge. Patient sprayed 0.2 ml of Verapamil 2 mg/ml into each nostril and directly into the back of the throat. Within minutes, patient experienced a reduction in nasal congestion and decreased nasal discharge. The nasal continued to slow and stopped after approximately 20 minutes.
- After a couple of hours the patient then continued to apply repeated small local applications of 0.1 ml intranasally and orally to throat twice more when the symptoms of nasal congestion started to recurred and again prior to going to sleep that night.
- When the patient awoke the next day the upper respiratory symptoms were cleared, but the patient began to experience lower respiratory infectious symptoms of an increasingly productive cough the next day. These lower respiratory symptoms worsened and by the following day the patient was experiencing extreme uncontrolled coughing episodes. The patient went on Verapamil 80 mg q6-8 hours. Prior to starring Verapamil, the patient had profuse clear mucus discharge from the lungs and was experiencing prolonged and frequent coughing spells. After taking his first dose of Verapamil, within 10-20 minutes the patient noticed a profound reduction in coughing and a significant reduction in volume of sputum being cleared from the lungs. Within 30-60 minutes of the first dose, the cough was infrequent and mostly non-productive. For the next four days, whenever the patient went beyond 6-8 hours of last 80 mg dose, he began to experience increasing productive coughing repeatedly demonstrating a relationship between declining serum Verapamil levels and increasing severity of his bronchitis/pulmonary symptoms and each time that the patient took the 80 mg Verapamil tablet there was a dramatic reduction in pulmonary discharge and reduction in coughing for over 6 hours before symptoms.
- Patient A with recurrent cold sores was given Diltizem 100 mg/ml and asked to apply topically at the first signs of a cold sore. The patient observed that in the initial tingling phase prior to the eruption if he applied the cream, the infection could be prevented and if application was delayed until eruption was visible, he could minimize the severity, reduce the size and complete healing clearance would occur in 2-4 days instead of lasting the usual 7 days.
- Patient B with recurrent cold sores was given Verapamil 200 mg/ml and asked to apply at the first signs of a cold sore. The patient observed that in the initial tingling phase if he applied the cream, the infection could be prevented and if application was delayed until eruption was visible, he could minimize the severity, reduce the size and complete healing clearance could occur in 2-4 days instead of lasting the usual 7 days.
- Male patient with a long history of recurrent Genital Herpes was using Diltiazem. When questioned by the inventor about the frequency of recurrences of his genital herpes before and after starting Diltiazem, the patient reported that before he was having several episode per year, and that after starting Diltiazem there had been only about 1-2 episodes per year, that they were much smaller and seemed to heal much quicker when on when Diltiazem.
- HIV patient took Verapamil 240 mg (120 mg of verapamilSR) twice daily for 2 weeks before repeat blood work and showed significant rise in T4 helper counts.
- A 39 year old woman with a three day history of fever, chills, muscle aches and nausea. On the second and third days the patient developed increasing diarrhea. On the morning of the third day the patient was experiencing loose, watery stools with a cramps and lower abdominal pain. Patient had 6 watery bowel movements and was going to the washroom frequently before starting Verapamil 120 mg tablets, taking one every 8 hours. Within one hour of taking the first Verapamil, the abdominal cramping began subsiding and her stools began to become more formed and diarrhea improved.
- Elderly patient with Herpes Zoster infection on the upper left abdomen. Patient took Verapamil 120 mg SR twice daily and noted reduced pain, reduced rash and rapid healing of lesions.
- Although this disclosure has described and illustrated certain preferred embodiments of the invention, it is to be understood that the invention is not restricted to those particular embodiments. Rather, the invention includes all embodiments which are functional or mechanical equivalent of the specific embodiments and features that have been described and illustrated.
- A 54 year old male surgeon with a latex glove allergy. Symptoms of a red eczematous rash develops when he uses latex gloves. This delayed hypersensitivity reaction is prevented by the application of Verapamil 200 mg/ml ointment prior to wearing latex gloves.
- Also the chronic rash that occurs from daily expose to latex was seen to improved within hours of the application of verapamil 200 mg/ml ointment.
- 64 year old female with Rheumatoid Arthritis and significant pain and disability in her hands noted a significant reduction of pain in her hand within hours of applying Verapamil or Diltiazem ointments. And patient reported improved mobility of joints with sustained applications over several days.
Claims (17)
1. A pharmaceutical composition for treatment and prevention of broad spectrum virus ailments comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
2. A composition as claimed in claim 1 , wherein said calcium channel blocker is verapamil.
3. A composition as claimed in claim 1 , wherein said calcium channel blocker is diltiazem.
4. A composition as claimed in claim 1 , wherein said calcium channel blocker is felodipine.
5. A composition as claimed in claim 1 , wherein said calmodulin blocker is trifluoperazine.
6. A composition as claimed in any one of claims 1 to 5 , wherein said composition is in the form of a cream, spray, mouth wash, gel, ointment or patch.
7. A composition as claimed in any one of claims 1 to 5 , wherein said composition is in the form of a tablet, a sustained release formulation for systemic use.
8. A composition as claimed in any one of claims 1 to 5 , wherein said composition is in the form of a sterile solution for parenteral injection.
9. A method for the treatment and prevention of broad spectrum virus ailments comprising administering to a human being a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
10. A method as claimed in claim 9 , wherein said calcium channel blocker is verapamil.
11. A method as claimed in claim 9 , wherein said calcium channel blocker is diltiazem.
12. A method as claimed in claim 9 , wherein said calcium channel blocker is felodipine.
13. A method as claimed in claim 9 , wherein said calmodulin blocker is trifluoperazine.
14. A method as claimed in claim 9 , wherein said administration comprises subcutaneous injection, high pressure jet device, intracavernous injection, intravenous injection, intramuscular injection, intradermal injection, intra-nasal or topical administration.
15. A method as claimed in claim 12 , wherein said administration is topical administration.
16. A method of manufacturing a medicament intended for the application of treating and preventing broad spectrum virus ailments characterized in that said medicament comprises a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof; and admixed with a pharmaceutical acceptable diluent or carrier.
17. A method as claimed in claim 16 , wherein said blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/146,010 US20210128514A1 (en) | 2009-12-03 | 2021-01-11 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US18/114,305 US20230233506A1 (en) | 2009-12-03 | 2023-02-27 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2687013 | 2009-12-03 | ||
CA2687013A CA2687013C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
PCT/CA2010/001926 WO2011066657A1 (en) | 2009-12-03 | 2010-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US201213513639A | 2012-06-04 | 2012-06-04 | |
US16/423,225 US10888541B2 (en) | 2009-12-03 | 2019-05-28 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US17/146,010 US20210128514A1 (en) | 2009-12-03 | 2021-01-11 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/423,225 Continuation US10888541B2 (en) | 2009-12-03 | 2019-05-28 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/114,305 Continuation US20230233506A1 (en) | 2009-12-03 | 2023-02-27 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210128514A1 true US20210128514A1 (en) | 2021-05-06 |
Family
ID=44114205
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/513,639 Active US10350190B2 (en) | 2009-12-03 | 2010-12-03 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US16/423,225 Active US10888541B2 (en) | 2009-12-03 | 2019-05-28 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US17/146,010 Abandoned US20210128514A1 (en) | 2009-12-03 | 2021-01-11 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US18/114,305 Pending US20230233506A1 (en) | 2009-12-03 | 2023-02-27 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/513,639 Active US10350190B2 (en) | 2009-12-03 | 2010-12-03 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
US16/423,225 Active US10888541B2 (en) | 2009-12-03 | 2019-05-28 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/114,305 Pending US20230233506A1 (en) | 2009-12-03 | 2023-02-27 | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker |
Country Status (4)
Country | Link |
---|---|
US (4) | US10350190B2 (en) |
EP (2) | EP3216453B1 (en) |
CA (2) | CA2687013C (en) |
WO (1) | WO2011066657A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3081325B1 (en) * | 2018-05-23 | 2020-10-09 | Univ Claude Bernard Lyon | DILTIAZEM FOR USE IN THE TREATMENT OF MICROBIAL INFECTIONS |
FR3106055B1 (en) | 2020-01-13 | 2022-01-28 | Centre Nat Rech Scient | COMBINATION OF DILTIAZEM AND OTHER ANTIVIRAL AGENTS |
FR3108033B1 (en) | 2020-03-10 | 2023-04-21 | Univ Claude Bernard Lyon | ANTIVIRAL COMPOUNDS AND THEIR COMBINATIONS FOR TREATING SARS-CoV-2 VIRAL INFECTION |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663317A (en) * | 1984-04-18 | 1987-05-05 | Board Of Regents, University Of Texas System | Methods and compositions for treating viral infections |
US20050080122A1 (en) * | 2002-01-31 | 2005-04-14 | Anderson David Andrew | Anti-viral compounds |
US20110126071A1 (en) * | 2008-08-11 | 2011-05-26 | Seung Hee Han | Method and apparatus of transmitting information in wireless communication system |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800081A (en) * | 1984-04-18 | 1989-01-24 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections |
EP0231266A1 (en) * | 1985-07-02 | 1987-08-12 | Key Pharmaceuticals, Inc. | Composition for the treatment of chronic obstructive pulmonary disease |
US4849412A (en) | 1986-06-05 | 1989-07-18 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections |
JPH04368338A (en) | 1991-06-12 | 1992-12-21 | Taisho Pharmaceut Co Ltd | Antitussive agent |
US7479498B2 (en) * | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
US20050245502A1 (en) * | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
US7470718B2 (en) | 2000-10-03 | 2008-12-30 | Albert Einstein College Of Medicine Of Yeshiva University | Method for treating a demyelinating condition |
WO2002038140A2 (en) * | 2000-11-09 | 2002-05-16 | Contrimmune Biotechnology Inc | Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
WO2003062388A2 (en) * | 2002-01-16 | 2003-07-31 | The Regents Of The University Of California | Inhibition of rna function |
WO2005089639A2 (en) * | 2004-03-16 | 2005-09-29 | Talarico M D Matthew T | Method for vascular dysregulation |
WO2010026602A2 (en) * | 2008-09-05 | 2010-03-11 | International Centre For Genetic Engineering And Biotechnology | Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis |
-
2009
- 2009-12-03 CA CA2687013A patent/CA2687013C/en active Active
- 2009-12-03 CA CA3013734A patent/CA3013734C/en active Active
-
2010
- 2010-12-03 EP EP17168653.8A patent/EP3216453B1/en active Active
- 2010-12-03 US US13/513,639 patent/US10350190B2/en active Active
- 2010-12-03 WO PCT/CA2010/001926 patent/WO2011066657A1/en active Application Filing
- 2010-12-03 EP EP10834131.4A patent/EP2506854B1/en active Active
-
2019
- 2019-05-28 US US16/423,225 patent/US10888541B2/en active Active
-
2021
- 2021-01-11 US US17/146,010 patent/US20210128514A1/en not_active Abandoned
-
2023
- 2023-02-27 US US18/114,305 patent/US20230233506A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663317A (en) * | 1984-04-18 | 1987-05-05 | Board Of Regents, University Of Texas System | Methods and compositions for treating viral infections |
US20050080122A1 (en) * | 2002-01-31 | 2005-04-14 | Anderson David Andrew | Anti-viral compounds |
US20110126071A1 (en) * | 2008-08-11 | 2011-05-26 | Seung Hee Han | Method and apparatus of transmitting information in wireless communication system |
Non-Patent Citations (9)
Title |
---|
Adamson, Chem. Soc. Rev., 2021, 50, 3647-55 (Year: 2021) * |
Calan Label (NDA 18-817/S-021, p 3-17, May 2009). (Year: 2009) * |
Cernik (https://jamanetwork.com/ journals/jamainternalmedicine/fullarticle/414294, 2008). (Year: 2008) * |
Enteroviruses (https://wiki.idph.iowa.gov/ Portals/3/userfiles/5/Files/Enteroviruses%20Fact%20sheet.pdf, 2004 (Year: 2004) * |
Hulisz (Pharmacy Times, Oct 1 2001) (Year: 2001) * |
Kaushar, Int J of Immunopathology & Pharmacology, 35, 1-12, 2021 (Year: 2021) * |
SD Dept (https://doh.sd.gov/diseases/infectious/diseasefacts/viral-respiratory.aspx, 2001). (Year: 2001) * |
Tompa, Int J of Biological Macromolecules, 2021, 524-541 (Year: 2021) * |
WO 2011126071 A1, see English translation (Year: 2011) * |
Also Published As
Publication number | Publication date |
---|---|
US10350190B2 (en) | 2019-07-16 |
US20230233506A1 (en) | 2023-07-27 |
WO2011066657A1 (en) | 2011-06-09 |
US10888541B2 (en) | 2021-01-12 |
CA2687013A1 (en) | 2011-06-03 |
US20190274992A1 (en) | 2019-09-12 |
CA3013734A1 (en) | 2011-06-03 |
US20120245145A1 (en) | 2012-09-27 |
CA2687013C (en) | 2018-09-04 |
CA3013734C (en) | 2020-01-14 |
EP2506854A1 (en) | 2012-10-10 |
EP3216453B1 (en) | 2019-05-15 |
EP2506854B1 (en) | 2017-05-03 |
EP2506854A4 (en) | 2013-05-22 |
EP3216453A1 (en) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210128514A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
US9387227B2 (en) | Method for treatment of sores and lesions of the skin | |
JP2505944B2 (en) | Pharmaceutical composition for treating asthma containing (S) -α-fluoromethyl-histidine and its ester | |
JP2000512270A (en) | Compositions and methods for the treatment of herpes simplex | |
US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
WO2010151004A2 (en) | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids | |
JPH01180822A (en) | Anti-delayed type allergic agent | |
TWI720396B (en) | Use of Pien Tze Huang and its preparations in treating neuralgia after herpes zoster | |
CA2130770A1 (en) | Treatment of upper respiratory tract infections | |
EP3294267A1 (en) | Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity | |
FOXWORTHY et al. | Adrenocorticotropin and cortisone in the treatment of severe Reiter's syndrome | |
AU2014267349A1 (en) | Agent and method for treating herpes | |
CN1208063C (en) | Chemical mixture and its use | |
EP2729137B1 (en) | Topical compositions for use in the prevention and/or treatment of dermatitis | |
CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
EP3006020B1 (en) | Method for treating recurring skin and mucous membrane diseases caused by hsv-1 and hsv-2 | |
CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
CN103585150A (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
CN117243948A (en) | Application of daphnetin-containing composition in preparation of rheumatic arthritis drugs | |
JP2003055206A (en) | Medicine composition for nasal cavity | |
US20100086625A1 (en) | Methods for treating skin lesions | |
CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
Turner et al. | Drugs Handbook 1993–94 | |
CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |